XML 48 R36.htm IDEA: XBRL DOCUMENT v3.23.2
Collaborations (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Collaborative and license agreements          
AbbVie's receivable from Janssen $ 11,491   $ 11,491   $ 11,254
AbbVie's payable to Janssen 27,036   27,036   25,402
Janssen Biotech Inc. | Collaborative arrangement          
Collaborative and license agreements          
Milestone payments 200   $ 200    
Share of collaboration development costs responsible by Janssen (as a percent)     60.00%    
Share of collaboration development costs responsible by the entity (as a percent)     40.00%    
Global - AbbVie's share of other costs (included in respective line items) 57 $ 69 $ 112 $ 133  
AbbVie's receivable from Janssen 268   268   295
AbbVie's payable to Janssen 295   295   $ 379
Janssen Biotech Inc. | Collaborative arrangement | United States          
Collaborative and license agreements          
Collaboration counterparty's share of collaborative arrangement expenses (included in cost of products sold) 312 404 609 812  
Janssen Biotech Inc. | Collaborative arrangement | International          
Collaborative and license agreements          
International - AbbVie's share of profits (included in net revenues) 241 283 481 582  
Genentech, Inc. | Collaborative arrangement          
Collaborative and license agreements          
Collaboration counterparty's share of collaborative arrangement expenses (included in cost of products sold) 214 196 416 374  
AbbVie's share of development costs (included in R&D) 30 31 58 58  
Genentech, Inc. | Collaborative arrangement | United States          
Collaborative and license agreements          
AbbVie's share of sales and marketing costs from U.S. collaboration (included in SG&A) $ 8 $ 5 $ 19 $ 17